Board summary
Key figures
43,171
Registered population
65.0% aged 18–64
12.1%
Aged 65+
ICB 21.9% · England 17.9%
27.0%
Ethnic minority (non-White)
15.6% Asian · England 9.6%
3.4%
In IMD quintile 1
ICB 9.2% · England 21.0%
~1,483
Core20 residents (est.)
Resident basis; registered basis ~1,336 · see page 3
6,509
Hypertension register
+22.04% in 3 yrs · England +5.60%
371
SMI register
29.1% of Crawley's
841
COPD register
Reviews -10.95% in 3 yrs
Forecast to 2030
9,497
Hypertension patients, 2030
+2,988 on today
67.8%
QRISK ≥20% on statins, 2030
+1.42pp over 3 yrs
3.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD and asthma reviews fell as registers grew.
COPD reviews fell -10.9% to 71.0% (England +2.8%) and asthma reviews fell -7.8% to 68.0% (estimated 938 unreviewed), which may reflect capacity pressures.
Deprivation and access pressures at Coachmans Medical Practice.
Coachmans Medical Practice holds all registered Core20 deprivation (13.6%, estimated 1,336 patients), with 42.3% phone ease and an 11.8 pp age 5 MMR gap.
Hypertension control under 80 and heart failure reviews.
Blood pressure control under 80 reaches 73.9% (England 67.8%), while heart failure reviews rose +27.1% over 2023 to 2025 to 84.1% (England 78.5%).
Population, age and ethnicity
Only 12.1% of patients are aged 65+ alongside 27.0% ethnic minority residents
South Crawley PCN serves 43,171 registered patients. The population is relatively young: 12.1% (5,217 patients) are aged 65+, below Crawley (13.7%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%), while 22.9% are aged 0-17 (Crawley 22.1%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Census estimates of usual residents in associated catchment areas—distinct from registered patients—show 27.0% are from ethnic minority groups, including 15.6% Asian / Asian British (Crawley 15.4%, NHS Sussex Integrated Care Board 3.7%, England 9.6%). This younger demographic profile may shift clinical demand toward paediatric services.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Crawley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Crawley LA) | 2,574 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Crawley LA) | 1,205 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Crawley LA) | 12.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 3.4% PCN-wide but concentrates entirely within Coachmans Medical Practice
South Crawley PCN has an average IMD decile of 4.7 and a 3.4% Core20 share, above Crawley (1.3%) but below NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Modelled practice-weighted Core20 is 3.1%, reflecting a slight reconciliation variance. Deprivation concentrates entirely at Coachmans Medical Practice (13.6% share, estimated 1,336 patients), while Saxonbrook Medical Centre, Gossops Green Medical Ctr and Bewbush Medical Centre record 0.0%. Across associated areas, an estimated 1,483 residents live in deciles 1 and 2, including 417 children aged 0-17 and 840 adults aged 18-64.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
371
SMI register
0.85% recorded prevalence
280
Learning disability register
0.64% recorded prevalence
11
Care homes, 215 beds
In the PCN catchment
8.7%
Provide unpaid care
Crawley, Census 2021
Recorded prevalence is 0.6% for learning disability (280 patients; Crawley 0.8%, NHS Sussex Integrated Care Board 0.6%, England 0.6%) and 0.8% for severe mental illness (371 patients; Crawley 0.9%, NHS Sussex Integrated Care Board 1.1%, England 1.0%). Catchment data records 11 care homes with 215 beds.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.8% (371 patients). Checks reach 81.7% for blood pressure (England 83.4%) and 76.9% for BMI (England 82.1%), trailing lowest at Gossops Green Medical Ctr (59.6% BP, 52.6% BMI).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,509
Hypertension register
+22.04%
Register growth, 3 yrs
Crawley +6.33% · England +5.60%
+3.47pp
BP control, under 80
≤140/90 · +1.13pp aged 80+
+2,988
More patients by 2030
Forecast 9,497 (22.12%)
Hypertension case-finding and control
The hypertension register reached 6,509 patients (14.8% prevalence; England 15.2%, NHS Sussex Integrated Care Board 16.3%, Crawley 13.8%), rising +22.0% over 2023 to 2025 (England +5.6%). Treatment to target reached 72.8% (England 70.3%, Crawley 74.2%), with blood pressure control for patients under 80 at 73.9% (England 67.8%). However, hypertensive patients with a recent blood pressure reading fell 0.3% over 2023 to 2025 (England +3.6%), reaching 90.2% (Crawley 93.2%). Practice prevalence is 13.2% at Coachmans Medical Practice, 15.7% at Saxonbrook Medical Centre, and 15.7% at Gossops Green Medical Ctr. Annual blood pressure checks fell behind national trends despite register growth, suggesting scope to strengthen recall.
Lipids and statins
Primary prevention statin coverage in diabetes is 64.4%, below England (73.2%) and falling 2.7% over 2023 to 2025 (England +2.1%), whereas QRISK ≥ 20% lipid therapy is 64.9% (England 63.6%). Statin coverage in primary prevention trails national benchmarks, highlighting scope to review eligible diabetic patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 55,355 | £2.10 | £2.42 | £1.86 | £116,246 |
| Cardiovascular (all), 2025 | 79,701 | £2.51 | £3.32 | £3.33 | £200,050 |
In 2026, lipid-modifying drugs totaled 55,355 items at £2.10 per item (£116,246 spend), costing £13,285 more than at England's unit cost (£1.86) but £17,714 less than NHS Sussex Integrated Care Board (£2.42; Crawley £2.34).
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.76%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+8.75%
Asthma prevalence, PCN 3-yr % change
Over 2023 to 2025, COPD (+36.1%, 841 patients) and asthma (+8.8%, 2,936 patients) registers expanded faster than England (+2.6% and +0.5%). Conversely, annual reviews fell 10.9% to 71.0% for COPD (England +2.8% to 76.4%) and fell 7.8% to 68.0% for asthma (England +4.4% to 65.7%), leaving an estimated 938 asthma patients unreviewed. Rapid register expansion may have outpaced review capacity, an unverified operational hypothesis.
Cancer register and children's immunisation
The cancer register records 1,239 patients (2.8% vs England 3.8%). In Q1 2025/26 supplementary childhood immunisation data (cohort 143), MMR dose 1 at age five reached 93.0%, but dose 2 dropped to 84.6%, an 8.4 pp second-dose gap. Coverage for the 4-in-1 booster was 83.2%, below the 95.0% target by 11.8 pp, indicating pre-school booster drop-off despite strong infant uptake.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022 across NHS Sussex ICB, 58.5% of staged cancers (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) but 16.5 percentage points below the 75.0% national ambition by 2028 (a gap of about 1,360 early-stage cases). Known stage was recorded for 64.3% of registered cancers (8,209 of 12,766). These ICB figures reflect wider system performance rather than PCN delivery. At PCN level, cervical screening coverage is 66.2% (Crawley 68.7%, England 66.8%), with Coachmans Medical Practice recording 63.7% and Gossops Green Medical Ctr recording 64.0%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), acute provider Surrey and Sussex Healthcare NHS Trust achieved 70.0% against the cancer 62-day referral to treatment standard (127 of 181.5 pathways), falling 15.0 percentage points below the 85.0% standard. This exceeds University Hospitals Sussex NHS Foundation Trust (65.2%), but trails Epsom and St Helier University Hospitals NHS Trust (86.8%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). Across diagnostic tests, 28.5% waited 6+ weeks at the provider (3,548 of 12,450), above England (23.1%). Provider metrics reflect wider system performance, not PCN delivery.
| Pathways within standard (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 74.01 | 89.70 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 76.79 | 99.16 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 65.20 | 86.82 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | England |
|---|---|---|---|---|
| MRI | 27.53 | 5.62 | 0.31 | 21.40 |
| CT | 18.49 | 8.57 | 1.06 | 9.92 |
| Echocardiography | 43.78 | 0.39 | 25.49 | 28.48 |
| Colonoscopy | 15.11 | 39.35 | 33.01 | 30.83 |
| Gastroscopy | 21.06 | 20.02 | 30.90 | 29.02 |
| All 15 DM01 tests | 28.50 | 12.95 | 6.83 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), Crawley borough residents recorded 78,050 community service contacts, with 56,740 contacts (72.7%) involving adults aged 65+. These local authority figures describe wider borough resident service contacts rather than direct PCN delivery.
Practice variation and patient experience
Phone access varies by 30.2 pp across practices while vaccination achievement spans 17.4 pp
In 2025/26, overall QOF achievement spanned from 85.9% at Coachmans Medical Practice to 94.3% at Gossops Green Medical Ctr (England 92.5%). Vaccination and immunisation achievement varied by 17.4 pp, from 32.1% at Bewbush Medical Centre to 49.5% at Gossops Green Medical Ctr, leaving every practice below England (55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Coachmans Medical | 103 | 13.6 | 42.3% | 66.4% | 75.8% |
| Gossops Green | 101 | 0.0 | 49.5% | 64.2% | 74.6% |
| Bewbush | 100 | 0.0 | 72.5% | 72.1% | 72.1% |
| Saxonbrook | 98 | 0.0 | 42.4% | 62.9% | 62.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
13 of 25 tracked measures trail England over three years, led by dementia
Across 25 tracked measures, 13 trailed England's three-year change. Over 2023 to 2025, dementia prevalence fell 9.7% (England +6.0%), while depression register growth was +1.6% (England +7.7%). Annual reviews also contracted: COPD reviews fell 10.9% (England +2.8%) and asthma reviews fell 7.8% (England +4.4%), alongside diabetes statin coverage, which fell 2.7% (England +2.1%). Three-year strengths include heart failure reviews (rose +27.1%, England +8.7%), psychosis alcohol recording (rose +10.2 pp, England +5.4 pp), and 2023 to 2024 breast screening coverage (rose +20.1%, England +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
COPD reviews
Asthma reviews
Depression register
Diabetes statin (no CVD)
Heart failure reviews
Breast screening (53-70)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Crawley | Asset | PCN | Crawley |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (215 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | 6 | 7 | Places of worship | 39 | 45 |
| Libraries | 2 | 2 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 9 | 10 | Primary academies | 11 | 14 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review completion is 68.0% of the 2,936 register (Crawley 68.7%, England 65.7%), falling 7.8% (-5.7 pp) over 2023 to 2025 (England +4.4%), leaving an estimated 938 unreviewed. For discussion: practices could run structured asthma recall using a shared template, flexible slots and inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Proactive COPD annual review recall
COPD review coverage is 71.0% across the 841 register, below Crawley (74.3%), NHS Sussex Integrated Care Board (74.2%) and England (76.4%), falling 10.9% over 2023 to 2025 (England +2.8%). For discussion: practices could establish proactive annual recall for the 841 COPD patients, prioritising deprived cohorts. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 143), age 5 4-in-1 booster coverage was 83.2%, below the 95.0% target by 11.8 pp and NHS Sussex ICB (85.8%), with an 8.4 pp MMR1-to-MMR2 gap (93.0% vs 84.6%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Tailored ethnic minority outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension monitoring recall (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Proactive COPD annual review recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN & Practice |
| Option 3 · Pre-school booster and MMR2 recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity test | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
